Latest News
In accordance with the provisions of Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation as amended and supplemented, the Competition Council makes available to the public the “summary of the operation” below, containing the information provided by the parties.
This information has been prepared by the notifying party, which is solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 as amended and supplemented for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.
Names of the companies and individuals involved:
- The acquirer: the company “Fidia Farmaceutici S.p.A.”;
- The target: pharmaceutical assets related to the company “Sanofi.SA”.
Nature of the operation
- Acquisition of assets.
Economic sectors concerned:
- Pharmaceutical sector.
Deadline for interested third parties to submit their observations:
- 10 days from the date of publication of this press release, i.e., May 24, 2024.
NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES
The Competition Council received notification of an economic concentration operation consisting of the acquisition by the company “Fidia Farmaceutici S.p.A.” of pharmaceutical assets currently held by the company “Sanofi SA”.
“Fidia Farmaceutici S.p.A.” is an Italian pharmaceutical company active in research and development, production, and marketing of health products.
“Sanofi SA” is a French company in the healthcare sector, focused on research, development, manufacturing, and marketing of health solutions.
Done in Rabat, May 9, 2024.
